Developing Mitochondria Based Therapeutics

Our proprietary platform technology is designed to rapidly identify therapeutically relevant peptides encoded within the mitochondrial genome, to evaluate their biological activity, and to develop these peptides into novel mitochondria based therapeutics (MBTs) that have the potential to treat diseases with major unmet medical needs.

Cohbar’s Platform Technology

We use a broad range of proprietary activity screens to assess the therapeutic potential of our novel peptides and to prioritize our development opportunities. Some of our novel peptides have demonstrated promising biological effects in a variety of in vitro and/or in vivo models of age-related diseases. We prioritize the research and development of our novel peptides by assessing their activity in a variety of biological areas. These assessments include metabolic regulation, oxidative stress, cellular energy levels, cell proliferation, cell death, cellular protection, carbohydrate metabolism, lipid metabolism, body weight regulation, regulation of body fat, insulin sensitivity, regulation of glucose, glucose tolerance, liver function, regulation of fibrotic processes, immunomodulatory effects, and tumor growth.

Platform Technology: Evaluation of over 100 peptides encoded in the mitochondrial DNA and their analogs for development into novel therapeutics

"New
Click Image to Enlarge